Treatment with Eptinezumab for Migraine Prevention in People with Chronic Migraine and Medication-Overuse Headache: A Plain Language Summary

Abstract

What is this summary about?

This is a summary of three articles describing preventive treatment of migraine in participants with a diagnosis of both chronic migraine and medication-overuse headache in a study called PROMISE-2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2). People living with chronic migraine and medication-overuse headache have one of the most disabling, costly, and difficult-to-treat headache disorders.

What were the results?

After preventive migraine treatment with eptinezumab (trade name Vyepti), participants with chronic migraine and medication-overuse headache experienced fewer migraine days, a reduced severity of migraine attacks, and a reduced use of acute medication. More participants receiving eptinezumab treatment no longer met the definition of either chronic migraine or medication-overuse headache throughout the study when compared with those receiving placebo.

What do the results mean?

Eptinezumab is beneficial for people who often use acute medication(s) due to frequent headache episodes or migraine attacks.

This is an abstract of the Plain Language Summary of Publication article.

To read the full Plain Language Summary of this article, click here to view the PDF.

Link to original article 1 here

Link to original article 2 here

Link to original article 3 here

Keywords::

• Acute medication
• Headache
• lay summary
• medication-overuse headache
• Migraine
• plain language summary
• preventive treatment

Acknowledgments

Thank you to the participants who took part in the PROMISE-2 study. Medical writing and editorial assistance in the development of this summary were provided by Emily Bolen and Nicole Coolbaugh, CMPP, of The Medicine Group, LLC (New Hope, PA). The PROMISE-2 study and medical writing support for this plain language summary of publications were funded by H. Lundbeck A/S.

Financial & competing interests disclosure

AJS has received consulting fees from AbbVie, Allergan, Amgen, Axsome Therapeutics, Eli Lilly, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Neurolief, Novartis, Satsuma, Teva, and Theranica. MK reports no conflicts to declare. RC and TB were employees of Lundbeck at the time of the PROMISE-2 study and original publications. Research and summary support were provided by H. Lundbeck A/S, Copenhagen, Denmark.

Additional information

Funding

AJS has received consulting fees from AbbVie, Allergan, Amgen, Axsome Therapeutics, Eli Lilly, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Neurolief, Novartis, Satsuma, Teva, and Theranica. MK reports no conflicts to declare. RC and TB were employees of Lundbeck at the time of the PROMISE-2 study and original publications. Research and summary support were provided by H. Lundbeck A/S, Copenhagen, Denmark.